Table of Contents
Conference Papers in Medicine
Volume 2013, Article ID 891072, 4 pages
Conference Paper

Biomarker Diagnostics in Acute Cardiac and Noncardiac Dyspnea: Is There a Role for Point-of-Care Testing?

Institute of Laboratory Medicine, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125 Berlin, Germany

Received 16 January 2013; Accepted 1 April 2013

Academic Editors: A. Bellou, E. Giannitsis, M. Möckel, and J. Searle

This Conference Paper is based on a presentation given by Dirk Peetz at “Clinical Decisions in Acute Patients: ACS–POCT–Hypertension and Biomarkers” held from 19 October 2012 to 20 October 2012 in Berlin, Germany.

Copyright © 2013 Dirk Peetz. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The use of biomarkers in acute chest pain and dyspnea is well established and point-of-care testing (POCT) is increasingly used in emergency departments and chest pain units for this purpose. However, few data give evidence that POCT has advantages for the patient or the medical process over central laboratory testing. Especially for troponin testing in patients with myocardial infarction, the newest guidelines define prerequisites on diagnostic test quality which most POC assays do not fulfill. Additionally, no data are available showing that POCT has relevant effect on a change of physician’s diagnostic and therapeutic thinking compared to laboratory testing. Regarding patient outcomes and societal costs, central laboratory testing seems to be even superior to POCT. The main limit of currently available POC troponin assays is the higher limit of detection and higher imprecision compared to the new high sensitive laboratory assays. However, new upcoming POC technologies may perform comparable to today’s laboratory analyzers.